Rinvoq orange book 2038?

Could you clarify what you mean by “Rinvoq orange book 2038”? A couple of possibilities:

- Do you want to know if Rinvoq (upadacitinib) is listed in the FDA’s Orange Book?
- Are you asking about patent or exclusivity dates that might extend to 2038?
- Or something else (specific TE status, NDC, etc.)?

Here’s the quick info and how to check:

- Rinvoq is upadacitinib, a JAK1 inhibitor, and is an FDA-approved brand-name product. The FDA Orange Book does include upadacitinib as an approved drug product. At present, there isn’t a widely available generic version, so a “therapeutic equivalence” (TE) code for a generic may not apply yet.
- The Orange Book is updated continuously; there isn’t a fixed “2038 edition.” To see the exact listing, search the Orange Book:
- FDA Orange Book site: https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- Use the search for “upadacitinib” or “Rinvoq” to view the entry, dosage forms, and any TE status.

If you want, I can look up the exact Orange Book entry for Rinvoq for you—just tell me if you want me to search the web. Also, if you’re asking about patent/exclusivity dates, I can help interpret those specifics once you confirm what exactly you need.